Clinical Trial

Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies. The beneficial health effects of consuming fish have traditionally been ascribed to the long-chain PUFA (LC-PUFA) EPA (C20:5n-3) and DHA (C22:6n-3), although consumption of fish oils or concentrates with high EPA and DHA contents does not affect the cholesterol concentration in humans and lowers the cholesterol concentration in rats and mice only when given in very high doses. Fish oils contain a plethora of fatty acids besides EPA and DHA, and in recent years, increased focus has been on the long-chain MUFA (LC-MUFA) cetoleic acid (C22:1n-11). Cetoleic acid is found in high amounts in oils from certain fish species such as herring, which has relatively low contents of both EPA and DHA. The investigators have recently summarised and meta-analysed the available literature that investigates the effects of diets containing fish oils or fish oil concentrates that have a high content of cetoleic acid but low or no content of EPA and DHA on cholesterol concentration in rodents, showing that cetoleic acid-rich fish oils and concentrates prevent high cholesterol concentration.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-10; most recent amendment 2025-09-28.
Status change: Recruiting → Active, Not Recruiting 2024-12-14
Status change: Not Yet Recruiting → Recruiting 2024-12-07
Trial Details
NCT Number NCT06364163
Lead Sponsor University of Bergen
Collaborators: The Norwegian Seafood Research Fund
Conditions High Cholesterol
Enrollment 80 participants
Start Date 2024-08-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02